Blue Lake Biotechnology Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$10M
Blue Lake Biotechnology General Information
Description
Developer of intranasal vaccines designed to protect the public from life-threatening diseases. The company uses a proprietary canine parainfluenza virus that undergoes several rounds of self-limited replication to induce immune responses, often with just a single dose, enabling doctors to provide a defense against infection and help reduce the spread of disease.
Contact Information
Website
www.bluelakebiotechnology.comCorporate Office
- 111 Riverbend Road
- Athens, GA 30602
- United States
Corporate Office
- 111 Riverbend Road
- Athens, GA 30602
- United States
Blue Lake Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 08-Nov-2022 | $10M | Completed | Clinical Trials - Phase 2 | ||
| 1. Seed Round | 06-Nov-2020 | Completed | Clinical Trials - Phase 2 |
Blue Lake Biotechnology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Blue Lake Biotechnology Patents
Blue Lake Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023372210-A1 | Recombinant rsv vaccine: methods of making and using the same | Pending | 04-Nov-2022 | ||
| EP-4611804-A1 | Recombinant rsv vaccine: methods of making and using the same | Pending | 04-Nov-2022 | ||
| US-12779029-B2 | Recombinant rsv vaccine: methods of making and using the same | Active | 04-Nov-2022 | ||
| US-20240148857-A1 | Recombinant rsv vaccine: methods of making and using the same | Active | 04-Nov-2022 | ||
| US-20260193671-A1 | Recombinant rsv vaccine: methods of making and using the same | Pending | 04-Nov-2022 | C12N15/86 |
Blue Lake Biotechnology Signals
Blue Lake Biotechnology FAQs
-
When was Blue Lake Biotechnology founded?
Blue Lake Biotechnology was founded in 2019.
-
Where is Blue Lake Biotechnology headquartered?
Blue Lake Biotechnology is headquartered in Athens, GA.
-
What is the size of Blue Lake Biotechnology?
Blue Lake Biotechnology has 15 total employees.
-
What industry is Blue Lake Biotechnology in?
Blue Lake Biotechnology’s primary industry is Drug Discovery.
-
Is Blue Lake Biotechnology a private or public company?
Blue Lake Biotechnology is a Private company.
-
What is Blue Lake Biotechnology’s current revenue?
The current revenue for Blue Lake Biotechnology is .
-
How much funding has Blue Lake Biotechnology raised over time?
Blue Lake Biotechnology has raised $18.8M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process